Verve Not Ready To Pull Plug On Anti-PCSK9 Gene Editing Candidate

But Firm Shifts Focus To Back-Up Candidate

The company told Scrip that the sixth patient with elevated liver enzymes and low platelets recovered after hospital observation and oral steroids, and it may still continue VERVE-101’s development.

• Source: Shutterstock

Verve Therapeutics, Inc. has paused enrollment in its Phase Ib Heart-1 trial of gene-edited cholesterol medicine VERVE-101 after a patient experienced liver enzyme elevations and low platelet counts. But while the company has decided to prioritize its development of a different asset with the same target, VERVE-102, it said VERVE-101 still might have a shot.

The biotech company said on 2 April that it had voluntarily paused enrollment in the study in heterozygous familial hypercholesterolemia...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Gene Therapies

Bluebird Builds Out Leadership Team Under Private Equity Ownership

 

The gene therapy developer appointed a new president, chief medical officer and chief of staff following the closing of its acquisition by private equity firms Carlysle and SK Capital.

Positive Fabry Data Should Smooth Way For Sangamo’s Partnering Efforts

 

The biotech announced results from the pivotal trial of isaralgagene civoparvovec and plans to file for approval in 2026 as it looks for a commercialization partner.

Saudi Arabia Plans Advanced Manufacturing Campus Under Biotech Drive

 
• By 

A partnership with Germfree Laboratories will bring a new facility to boost Saudi Arabia’s biotech sector as the world’s largest oil exporter tries to establish itself as a global biotech hub by 2040.

Syncona Looks To Go Private As Market Decline Deepens

 

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

More from Advanced Therapies

Positive Fabry Data Should Smooth Way For Sangamo’s Partnering Efforts

 

The biotech announced results from the pivotal trial of isaralgagene civoparvovec and plans to file for approval in 2026 as it looks for a commercialization partner.

Saudi Arabia Plans Advanced Manufacturing Campus Under Biotech Drive

 
• By 

A partnership with Germfree Laboratories will bring a new facility to boost Saudi Arabia’s biotech sector as the world’s largest oil exporter tries to establish itself as a global biotech hub by 2040.

Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By 

The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.